Latest On Eisai Co., Ltd (ESALY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-17 10:22 EST | News | Eisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBC | N/A |  |
| 2023-01-05 16:48 EST | News | Biogen makes changes to R&D department on eve on FDA lecanemab decision | N/A | |
| 2022-12-20 04:01 EST | News | Catalyst Pharma gains U.S. rights to Eisai epilepsy drug Fycompa | N/A | |
| 2022-10-06 19:36 EST | News | Bipartisan bill aims to get CMS to cover Alzheimer's antibody treatments | N/A | |
| 2022-09-29 18:47 EST | News | Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug | N/A | |
| 2022-09-29 03:28 EST | News | Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval | N/A | |
| 2022-09-29 03:28 EST | News | Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data | N/A | |
| 2022-09-27 20:13 EST | News | Biogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trial | N/A | |
| 2022-08-05 11:11 EST | News | Eisai GAAP EPS of ¥167.25, revenue of ¥756.22M misses by ¥433.78M | N/A | |
| 2022-04-09 00:23 EST | News | Biogen slips as analysts react to final Medicare decision on Alzheimer’s therapy | N/A | |
| 2022-04-08 08:10 EST | News | Biogen lower as Medicare officially limits coverage for Alzheimer’s drug | N/A | |
| 2022-03-04 15:00 EST | News | Biogen, Eisai begin filing application data for Alzheimer's drug lecanemab in Japan | N/A | |
| 2022-01-19 21:16 EST | News | Eisai's reports dosing of antibody therapy E2814 in phase 2/3 Alzheimer's disease trial | N/A | |
| 2022-01-06 05:37 EST | News | Roivant Sciences licenses transfusion-dependent anemia treatment from Eisai | N/A | |
| 2021-12-24 00:38 EST | News | Biogen price target cut at BofA on Japan refusing to approve Aduhelm | N/A | |
| 2021-12-22 08:18 EST | News | Biogen/ Eisai trial data on Alzheimer’s drug inconsistent - Japanese health ministry | N/A | |
| 2021-12-20 18:30 EST | News | Biogen halves price of Alzheimer’s drug in U.S. | N/A | |
| 2021-12-17 14:26 EST | News | Biogen and Eisai suffer setback for European approval of Alzheimer’s drug | N/A | |
| 2021-12-16 18:12 EST | News | Biogen plans post-marketing study on Aduhelm benefit to start in May 2022 | N/A | |
| 2021-11-22 14:35 EST | News | Biogen’s new Alzheimer’s drug caused brain swelling among 35% of patients in study | N/A | |
| 2021-11-19 03:15 EST | News | Biogen yet to convince payors for new Alzheimer’s drug, Bloomberg survey reveals | N/A | |
| 2021-09-28 06:55 EST | News | Biogen, Eisai begin rolling submission of lecanemab BLA for early Alzheimer's disease | N/A | |
| 2021-08-20 15:19 EST | News | Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg | N/A | |
| 2021-08-04 19:37 EST | News | HHS to review FDA’s accelerated pathway after approval of Biogen’s Alzheimer’s drug | N/A | |
| 2021-07-22 12:24 EST | News | Could Lilly's donanemab, others for Alzheimer's get a boost from Biogen approval? | N/A | |
| 2021-07-22 12:22 EST | News | Alzheimer's-focused Anavex takes a breather day after gaining 35% | N/A | |
| 2021-07-22 12:20 EST | News | Could Bristol's up to $3B Eisai deal follow in footsteps of 2019 AstraZeneca deal with Daiichi? | N/A | |
| 2021-07-22 12:20 EST | News | Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight | N/A | |
| 2021-07-22 12:18 EST | News | Biogen won approval for Alzheimer’s therapy while FDA staff raised concerns | N/A | |
| 2021-07-22 12:18 EST | News | Biogen, Eisai respond to questions surrounding approval of Alzheimer's drug Aduhelm | N/A | |
| 2021-07-22 12:17 EST | News | Biogen met with key FDA official, launched Project Onyx to gain Aduhelm approval - STAT | N/A | |
| 2021-07-22 12:14 EST | News | FDA was divided on a broader label for Biogen’s Alzheimer’s therapy: Stat News | N/A | |
| 2021-07-22 12:14 EST | News | Biogen tumbles as FDA chief calls for a probe on Alzheimer’s drug approval | N/A | |
| 2021-07-22 12:14 EST | News | Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says | N/A | |
| 2021-07-22 12:14 EST | News | Biogen to come under federal probe; pressures other developers in Alzheimer’s space | N/A | |
| 2021-07-22 12:12 EST | News | FDA chief indicates lapses in approval of Biogen’s Alzheimer’s therapy | N/A | |
| 2021-07-22 12:11 EST | News | UnitedHealth says need more info to determine coverage for Biogen’s Alzheimer’s therapy | N/A | |
| 2021-02-15 12:54 EST | Analyst Rating | The Analyst Target Price has decreased from $83.81 to $80.95. | Sell | |
| 2021-02-06 04:57 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-02 17:47 EST | News | Eisai and BioLabs partner to create the Eisai Innovation Center Biolabs | N/A | |
| 2020-11-26 22:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 14:12 EST | Analyst Rating | The Analyst Target Price has decreased from $100 to $83.81. | Neutral | |
| 2020-11-17 13:24 EST | Analyst Rating | The Analyst Target Price has decreased from $112.38 to $100. | Neutral | |
| 2020-11-10 05:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 21:30 EST | News | Biogen's long and winding road in Alzheimer's hits wall | N/A | |
| 2020-11-07 18:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 13:23 EST | Analyst Rating | The Analyst Target Price has increased from $100 to $112.38. | Buy | |
| 2020-11-04 17:23 EST | News | Biogen rallies 31% ahead of Ad Com meeting on Alzheimer's med aducanumab | N/A | |
| 2020-09-26 14:57 EST | Financials | Company financials have been released. | Neutral | |
About Eisai Co., Ltd (ESALY):
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
General
- Name Eisai Co., Ltd
- Symbol ESALY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 10,998
- Fiscal Year EndMarch
- IPO Date1961-09-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.eisai.co.jp
View More
Valuation
- Trailing PE 33.86
- Forward PE 27.25
- Price/Sales (Trailing 12 Mt.) 3.11
- Price/Book (Most Recent Quarter) 3.28
- Enterprise Value Revenue 0.03
- Enterprise Value EBITDA 0.13
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 13%
- Return on Assets 6%
- Return on Equity 14%
- Earnings Per Share $2.08
- Revenue Per Share $0
- Gross Profit 519.93 billion
- Quarterly Earnings Growth -3%
View More
Highlights
- Market Capitalization 20.05 billion
- Analyst Target Price $80.95
- Book Value Per Share $19.95
View More
Share Statistics
- Shares Outstanding 286.58 million
- Shares Float 285.78 million
- % Held by Insiders <1%
- % Held by Institutions 0.09%
View More
Technicals
- Beta 0.48
- 52 Week High $102.2
- 52 Week Low $56.08
- 50 Day Moving Average 71.74
- 200 Day Moving Average 78.03
View More
Dividends
- Forward Annual Dividend Rate $1.51
- Forward Annual Dividend Yield 2.15%
- Payout Ratio 35%
- Dividend Date 2016-11-28
- ExDividend Date 2020-09-28
- Dividend Per Share $1.36
- Dividend Yield 0%
View More
Eisai Co., Ltd (ESALY) Dividend Calendar:
ESALY's last dividend payment was made to shareholders on November 28, 2016.
Eisai Co., Ltd pays out 35% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Eisai Co., Ltd (ESALY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-03 | $N/A | $0.65 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.65 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.05 | $42.20 | -99.89% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.79 | ||
| 2019-12-31 | 2020-03-31 | $1.72 billion | $1.57 | ||
| 2019-09-30 | 2019-12-31 | $1.34 billion | $1.49 | ||
| 2019-06-30 | 2019-09-30 | $1.42 billion | $0.17 | ||
| 2019-03-31 | 2019-06-30 | $1.58 billion | $0.70 | ||
| 2018-12-31 | 2019-03-31 | $1.43 billion | $0.74 | ||
| 2018-09-30 | 2018-12-31 | $1.38 billion | $0.23 | ||
| 2018-06-30 | 2018-09-30 | $1.38 billion | $0.62 | ||
| 2018-03-31 | 2018-06-30 | $1.51 billion | $0.39 | ||
| 2017-12-31 | 2018-03-31 | $1.37 billion | $0.78 | ||
| 2017-09-30 | 2017-12-31 | $1.27 billion | $0.29 | ||
| 2017-06-30 | 2017-09-30 | $1.26 billion | $0.28 | ||
| 2017-03-31 | 2017-06-30 | $1.33 billion | $0.30 | ||
| 2016-12-31 | 2017-03-31 | $837.55 million | $0.03 | ||
| 2016-09-30 | 2016-12-31 | $1.33 billion | $0.31 | ||
| 2016-06-30 | 2016-09-30 | $1.33 billion | $0.28 | ||
| 2016-03-31 | 2016-06-30 | $1.33 billion | $0.67 | ||
| 2015-12-31 | 2016-03-31 | $1.25 billion | $0.52 | $21.80 | -97.63% |
| 2015-09-30 | 2015-12-31 | $1.16 billion | $0.79 | ||
| 2015-06-30 | 2015-09-30 | $1.14 billion | $0.16 | $9.50 | -98.29% |
| 2015-03-31 | 2015-06-30 | $1.16 billion | $0.16 | ||
| 2014-12-31 | 2015-03-31 | $954.71 million | $0.19 | $24.00 | -99.21% |
| 2014-09-30 | 2014-12-31 | $1.14 billion | $0.77 | ||
| 2014-06-30 | 2014-09-30 | $1.31 billion | $0.15 | $20.30 | -99.26% |
| 2014-03-31 | 2014-06-30 | $1.57 billion | $0.20 | ||
| 2013-12-31 | 2014-03-31 | $1.13 billion | $0.12 | ||
| 2013-09-30 | 2013-12-31 | $1.57 billion | $0.06 | ||
| 2013-06-30 | 2013-09-30 | $1.55 billion | $0.65 | ||
| 2013-03-31 | 2013-06-30 | $1.11 billion | $0.33 | ||
| 2012-12-31 | 2013-03-31 | $732.76 million | $0.53 | ||
| 2012-09-30 | 2012-12-31 | $2.41 billion | $0.39 | ||
| 2012-06-30 | 2012-09-30 | $1.84 billion | $0.57 | ||
| 2012-03-31 | 2012-06-30 | $1.31 billion | $0.52 | ||
| 2011-12-31 | 2012-03-31 | $2.26 billion | $0.40 | ||
| 2011-09-30 | 2011-12-31 | $2.22 billion | $0.72 | ||
| 2011-06-30 | 2011-09-30 | $2.07 billion | $0.90 | ||
| 2011-03-31 | 2011-06-30 | $1.77 billion | $0.59 | ||
| 2010-12-31 | 2011-03-31 | $2.58 billion | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $2.63 billion | $1.19 | ||
| 2010-06-30 | 2010-07-30 | $2.31 billion | $0.72 |
Eisai Co., Ltd (ESALY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Eisai Co., Ltd (ESALY) Chart:
Eisai Co., Ltd (ESALY) News:
Below you will find a list of latest news for Eisai Co., Ltd (ESALY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Eisai Co., Ltd (ESALY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Eisai Co., Ltd (ESALY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2002-11-14 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999702060324/9999999997-02-060324-index.htm |
| 2003-05-19 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999703021976/9999999997-03-021976-index.htm |
| 2003-07-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999703028722/9999999997-03-028722-index.htm |
| 2003-08-05 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999703031598/9999999997-03-031598-index.htm |
| 2003-11-12 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999703041616/9999999997-03-041616-index.htm |
| 2004-02-05 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999704004531/9999999997-04-004531-index.htm |
| 2004-05-17 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999704022729/9999999997-04-022729-index.htm |
| 2004-08-05 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999704032392/9999999997-04-032392-index.htm |
| 2004-09-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999704039290/9999999997-04-039290-index.htm |
| 2005-02-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705004714/9999999997-05-004714-index.htm |
| 2005-03-04 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705008047/9999999997-05-008047-index.htm |
| 2005-05-20 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999705027663/9999999997-05-027663-index.htm |
| 2005-06-17 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705028645/9999999997-05-028645-index.htm |
| 2005-07-14 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705031679/9999999997-05-031679-index.htm |
| 2005-07-25 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705032716/9999999997-05-032716-index.htm |
| 2005-08-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705034873/9999999997-05-034873-index.htm |
| 2005-11-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999705045205/9999999997-05-045205-index.htm |
| 2006-02-16 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706005552/9999999997-06-005552-index.htm |
| 2006-06-02 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706023029/9999999997-06-023029-index.htm |
| 2006-06-02 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999706023094/9999999997-06-023094-index.htm |
| 2006-07-25 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706031433/9999999997-06-031433-index.htm |
| 2006-08-15 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706035125/9999999997-06-035125-index.htm |
| 2006-09-14 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706038456/9999999997-06-038456-index.htm |
| 2006-11-27 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706047053/9999999997-06-047053-index.htm |
| 2006-12-04 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999706047585/9999999997-06-047585-index.htm |
| 2007-02-16 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707006442/9999999997-07-006442-index.htm |
| 2007-05-01 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707022102/9999999997-07-022102-index.htm |
| 2007-05-22 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999707025078/9999999997-07-025078-index.htm |
| 2007-07-16 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707033082/9999999997-07-033082-index.htm |
| 2007-08-07 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707036082/9999999997-07-036082-index.htm |
| 2007-10-18 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707044867/9999999997-07-044867-index.htm |
| 2007-11-14 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707047906/9999999997-07-047906-index.htm |
| 2007-12-18 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999707051925/9999999997-07-051925-index.htm |
| 2007-12-28 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708000121/9999999997-08-000121-index.htm |
| 2008-02-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708005635/9999999997-08-005635-index.htm |
| 2008-04-17 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708019822/9999999997-08-019822-index.htm |
| 2008-05-23 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/948406/999999999708025547/9999999997-08-025547-index.htm |
| 2008-06-10 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708027620/9999999997-08-027620-index.htm |
| 2008-06-26 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708030047/9999999997-08-030047-index.htm |
| 2008-08-11 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/948406/999999999708035269/9999999997-08-035269-index.htm |